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Cancer is a significant cause of death worldwide.1,2 Treatment consists of surgery, radiation 
therapy, and systemic therapy. Monoclonal antibodies (mAb) have become an increasing 
part of the systemic treatment of cancer.3 With the landscape-transforming arrival of 
cancer immunotherapy, such as drugs that block immune checkpoints, durable responses 
are observed for several different cancer types, including melanoma and non-small-cell 
lung cancer. Regrettably, only part of the patients initially respond, and once responded, 
resistance to immune checkpoint blockade may occur.4 Therefore, new treatment options are 
explored to enhance the immune system. These approaches include engaging T cells or inhibit 
immunosuppressive cell types like tumor-associated macrophages (TAMs). 
By redirecting T cells to infiltrate the tumor, T cells might release their cytotoxic 
potential.5 Bispecific T cell engagers (BiTEs) or T cell-directed bispecific antibodies redirect 
T cells to a predefined tumor target. BiTEs redirect T cells by the CD3ε binding arm and 
the other arm directed at the tumor target. Tumor targets include epithelial cell adhesion 
molecule (EpCAM), carcinoembryonic antigen (CEA) and glypican 3 (GPC3). Upon the 
simultaneous binding of a T cell to CD3ε and its tumor target, T cells become activated and 
can kill tumor cells in an antigen-specific manner. The CD19 BiTE blinatumomab is the 
only bispecific anticancer drug approved.5 For solid malignancies, multiple T cell-directed 
bispecific antibody-based immunotherapeutics are in development.6 
TAMs in the tumor microenvironment can act as an immunosuppressive cell type 
promoting tumor progression.7 Targeting TAMs by for example targeting the survival 
pathway colony-stimulating factor 1 (CSF1)/CSF1 receptor (CSF1R) using mAbs, promotes 
the anti-tumor effect of other treatment strategies in preclinical cancer models. Multiple TAM 
targeting approaches are being evaluated in clinical trials.7 
Limited information is available regarding the pharmacological behavior of these new 
molecular entities. Radiolabeling these types of drugs with positron emission tomography 
(PET) isotopes allows molecular imaging using PET to assess whole-body drug distribution 
and tumor targeting. Ex vivo, techniques like tissue autoradiography, radioactive gel 
electrophoresis of plasma or tissue lysate, and ex vivo biodistribution complement PET 
imaging. Thus, information is obtained on respectively intratumoral drug distribution, tracer 
integrity, and quantitative organ distribution. Overall, molecular imaging of radiolabeled 
drugs could provide information to support drug development. 
The research described in this thesis aims to gain insight in the pharmacological behavior 
of antibody-based immunotherapeutics using molecular imaging. 
In chapter 1, the background and outline of this thesis are described. In chapter 2, we 
aimed to define the role of molecular imaging in cancer drug development. We searched 
the literature with a focus on molecular imaging in the context of target expression, 
pharmacokinetics, and pharmacodynamics in cancer. We provide applications of molecular 
imaging regarding small-molecule cancer drugs, including inhibitors of epidermal growth 
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factor receptor, anaplastic lymphoma kinase, and poly(adenosine diphosphate ribose) 
polymerase. Also, molecular imaging applications of monoclonal antibodies are highlighted 
for growth factor receptors, immuno-oncology, and antibody-drug conjugates.
Furthermore, examples of monitoring pharmacodynamic responses upon anti-hormonal 
treatment using molecular imaging have been reported. Molecular imaging can answer 
multiple questions regarding in vivo drug behavior. Together with complementary techniques 
such as genomics, transcriptomics or proteomics, molecular imaging can serve as a tool to 
improve biomarker discovery, patient selection, and gain insight into drug mechanism of 
action and target engagement. 
Radiolabeling new cancer therapeutics allows us to study tumor targeting and whole-
body biodistribution. A new class of cancer therapeutics is BiTEs, a 55-kDa drug comprised 
of two single-chain Fv binding CD3ε and a tumor-associated antigen. AMG 110 is such a 
BiTE, directed at CD3ε on T cells and EpCAM on tumor cells, which is often overexpressed 
in epithelial malignancies. In chapter 3, we aimed to assess the tumor-targeting properties of 
zirconium-89 (89Zr) labeled and fluorescently labeled AMG 110 in xenograft bearing mice. 
Tumor uptake of 89Zr-AMG110 in an EpCAM positive xenograft was clearly visualized by 
PET imaging up to 72 hours after intravenous administration. Tumor uptake peaked at 6 and 
24 hours after 89Zr-AMG110 administration, reaching around 5% injected dose per gram of 
tissue. EpCAM negative xenografts were barely visible on PET images. Fluorescently labeled 
AMG 110 showed intratumoral distribution associated with viable tumor tissue. A non-
tumor targeting BiTE predominantly localized to necrotic tumor tissue. Together the data 
in this chapter showed proof-of-concept ability of BiTEs to distribute to tumor tissue in an 
antigen-dependent fashion.
AMG 110 showed limited anti-tumor efficacy and dose-limiting toxicity associated 
with physiological gastrointestinal EpCAM expression.8 The development of AMG 110 was 
subsequently discontinued. To improve the anti-tumor efficacy of the BiTE platform for 
solid tumors, a more restrictive tumor antigen is required. This led to the development of 
AMG 211, targeting human CEA, a pronounced tumor-associated antigen in gastrointestinal 
malignancies. We aimed to determine its tumor-targeting properties and biodistribution. For 
this, 89Zr-labeled and fluorescently labeled AMG 211 were studied in preclinical xenograft 
models in chapter 4. On top of in vivo distribution, we used ex vivo techniques to study 
AMG 211 integrity and intratumoral distribution. Finally, we manufactured 89Zr-AMG211, 
according to Good Manufacturing Practice (GMP), for a future clinical trial. 89Zr-AMG211 
showed dose-dependent tumor uptake at 6 hours after intravenous administration. The highest 
tumor uptake was observed with 2 µg and lowest tumor uptake with 500 µg of 89Zr-AMG211. 
Also, PET visualized only CEA positive xenografts after 10 µg administration at 24 hours after 
89Zr-AMG211 administration. Despite an elimination half-life of approximately 1 hour, the 
tumor retained tracer uptake for at least 24 hours. 89Zr-AMG211 showed a time-dependent 
and tumor-specific disintegration, resulting in low molecular weight species over 50% at 24 
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hours. Fluorescently labeled AMG211 localized predominantly to viable CEA-positive tumor 
tissue. Lastly, 89Zr-AMG211 was successfully manufactured according to GMP guidelines, 
fulfilling all predefined release specifications. This study illustrated the feasibility for assessing 
the in vivo pharmacological behavior and tumor-targeting properties of 89Zr-AMG211 in a 
preclinical setting, and GMP-compliance allowed for a subsequent clinical study. 
In the preclinical setting, as described in chapter 4, physiological tissue expression of 
human CEA and human CD3ε were absent. Therefore in chapter 5, we aimed to characterize 
the biodistribution and tumor uptake of 89Zr-AMG211 in a first-in-human study. This two-
center, molecular PET imaging phase I study was performed in patients with advanced 
gastrointestinal adenocarcinomas. We studied the biodistribution of 89Zr-AMG211 in healthy 
tissues and tumor lesions before and/or directly succeeding AMG 211 treatment. Patients 
received 37 MBq 89Zr-AMG211 intravenously with or without unlabeled AMG 211. Following 
tracer infusion, adverse events were monitored and graded according to NCI CTCAE v 4.03.9 
Before AMG 211 treatment, optimal imaging dose was 200 µg 89Zr-AMG211 and 1,800 µg 
unlabeled AMG 211. This dose resulted in a mean standardized uptake value (SUVmean) 
of 4.0 in the blood pool 3 hours after intravenous tracer administration. PET imaging 
revealed CD3ε-mediated uptake in spleen and bone marrow, with corresponding SUVmean 
of 3.2 and 1.8, respectively. Of 43 visible tumor lesions, 37 were quantifiable with PET with 
a median maximum SUV of 4.0 (interquartile range 2.7 - 4.4). Within and between patients, 
heterogeneity in tumor uptake was reflected by a 5-fold and 9-fold difference, respectively. Ex 
vivo analysis showed intact 
89Zr-AMG211 in the blood plasma and disintegrated species in 
the urine. After AMG 211 treatment, 89Zr-AMG211 was present in the circulation but was 
unable to visualize tumor lesions. The data presented in this chapter showed an accumulation 
of 89Zr-AMG211 in CD3ε-rich lymphoid tissues, as well as a clear, inter- and intra-individual 
heterogeneous tumor uptake. 
BiTEs are relatively small antibody-based therapeutics with serum half-lives of only 
several hours.5 They are prone to be eliminated from the circulation by kidneys due to the 
55-kDa size. Consequently, BiTEs are administered through continuous intravenous infusion 
to achieve stable serum levels and, thereby, sufficient drug exposure.5 Using a full-sized 
bispecific antibody format of around 150 kDa, circulating half-lives usually range from days 
to weeks in human, allowing a more patient-friendly dosing scheme. An example of such 
a full-sized T cell-redirecting antibody is ERY974, targeting CD3ε on T cells and glypican 
3 on tumor cells. Glypican 3 is overexpressed by several solid tumors, including a majority 
of hepatocellular carcinoma and a subset of breast cancers.10 In chapter 6, we radiolabeled 
ERY974 with 89Zr and studied its biodistribution by PET imaging in both xenograft-bearing 
immunodeficient as immunoproficient mouse models reconstituted with human immune 
cells. 89Zr-labeled control antibodies targeting CD3ε and non-mammalian protein keyhole 
limpet hemocyanin (KLH) or KLH only served to determine the impact of each arm on 
its biodistribution. Information on deep tissue distribution was obtained by ex vivo tissue 
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autoradiography. In immunodeficient mice, 89Zr-ERY974 tumor uptake was dependent on 
tumoral GPC3 expression. In mice engrafted with human immune cells, 89Zr-ERY974 tumor 
uptake was higher than for the same xenograft in immunodeficient mice. Ex vivo tissue 
autoradiography demonstrated preferential accumulation of 89Zr-ERY974 in stromal T-cell 
rich infiltrate. Next to the tumor, the highest uptake for 89Zr-ERY974 was observed in the 
spleen and lymph nodes. This study allows for a future clinical trial with 89Zr-ERY974 to 
study its pharmacological behavior in patients with cancer.
In contrast to cytotoxic T cells, TAMs play an important role in creating an 
immunosuppressive tumor microenvironment, thereby promoting cancer progression. 
TAMs are known to be involved in breast cancer progression.11 In a meta-analysis including 
over 2,000 patients with all-stage breast cancer, high TAM infiltration in the primary tumor 
predicted worse patient prognosis.12 In chapter 7, we aimed to define the landscape of the role 
of TAMs in breast cancer. We reviewed the available literature and clinical trials to identify the 
influence of TAMs on tumor progression and potential targets to alter TAM biology. TAMs 
are associated with poor prognosis in patients with breast cancer. In the preclinical setting, 
TAMs were found to promote breast cancer growth, invasion, and metastasis. In addition, we 
pointed out that TAMs mediate resistance to chemotherapy, radiotherapy, targeted therapy, 
and immunotherapy in mouse models of mammary carcinoma. Furthermore, we provided 
an overview of clinical trials with therapeutics targeting TAMs. Based on this data, targeting 
TAMs is a potential therapeutic strategy for breast cancer.
Targeting TAMS by inhibiting the pro-survival axis CSF1/CSF1R with mAbs is currently 
evaluated in clinical trials, as described in chapter 7. However, limited information is available 
regarding the biodistribution and tumor-targeting of such mAbs. Therefore in chapter 8, 
we radiolabeled an anti-murine CSF1R mAb to evaluate its biodistribution. For this, we 
used an immunocompetent mouse model of mammary carcinoma. First, the distribution 
of 89Zr-CSF1R-mAb to healthy tissues was determined in non-tumor-bearing mice in a 
dose-escalation study. Ex vivo autoradiography and immunohistochemistry were served to 
study the intratumoral distribution of 89Zr-CSF1R-mAb and the presence of TAMs. Next in 
tumor-bearing mice, the biodistribution of 89Zr-CSF1R-mAb was compared to a 89Zr-labeled 
isotype control. In non-tumor-bearing mice, 10 mg/kg resulted in circulating levels of 89Zr-
CSF1R-mAb for up to 72 hours. In contrast, 0.4 mg/kg 89Zr-CSF1R-mAb distributed mainly 
to spleen and liver, resulting in no tracer in the circulation at 24 hours after administration. 
In a mammary tumor model, 10 mg/kg 89Zr-CSF1R-mAb resulted in higher uptake in liver, 
lymphoid tissues, duodenum, and ileum, but not in tumor compared to 89Zr-labeled isotype 
control at 72 hours. Tissue autoradiography demonstrated CSF1R-specific localization of 89Zr 
in lymphoid tissues. Following 89Zr-CSF1R-mAb administration, TAMs were near absent 
as assessed by immunohistochemistry, whereas over 500 TAMs per mm2 were observed 
after 89Zr-labeled control. We hypothesize that the depletion of TAMs resulted in lower 
tumor uptake of 89Zr-CSF1R-mAb compared to 89Zr-labeled isotype control. In this study, 
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we provided data that show the potential of evaluating molecular imaging of macrophage-
targeting therapeutics in clinical trials to understand their pharmacological behavior. 
In conclusion, this thesis describes the development, characterization, and in vivo 
evaluation of radiolabeled antibody or antibody constructs to study its biodistribution and 
tumor targeting properties. 
GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Pharmacological behavior of T cell-directed therapeutics and new drug classes
Not all patients benefit from current cancer therapies. Therefore, new treatment modalities 
are explored. The drug distribution of such novel modalities is often poorly understood. As 
summarized in chapter 2, molecular imaging allows studying whole body drug distribution, 
target visualization, and heterogeneity in drug target expression, thereby supporting drug 
development. In chapters 3, 4, 5, and 6, we studied the biodistribution of a new class of drugs, 
namely T cell-directed bispecific antibody-based therapeutics. We showed distribution to 
the tumor in both the preclinical and the clinical setting. In an environment with CD3ε, 
the CD3ε binding arm also directs the bispecific drug to lymphoid tissues such as spleen 
and lymph nodes. So far, there are no approved T cell-directed bispecific therapeutic in the 
solid tumor setting. However, different novel formats are being developed, such as half-life 
extended versions or a full-sized antibody with a 2:1 format, creating bivalent tumor binding 
and monovalent T cell binding.6 Molecular imaging with these new compounds might gain 
additional insight into solid tumor targeting of T cell-directed bispecific antibody therapeutics. 
Besides the bispecific antibody class, other new approaches, such as gene therapy using 
oligonucleotides or cell therapy using chimeric antigen receptor (CAR) engineered T cells, 
are being developed. However, information about the pharmacological behavior of these 
therapeutics is scarce. By incorporating a PET reporter gene into a CAR T cell construct, 
PET imaging allows longitudinal tracking of CAR T cells. Several studies have demonstrated 
the potential of this approach, including a small clinical trial in patients with recurrent 
glioma.13-16 Monitoring the persistence of CAR T cells in the tumor might provide additional 
insight next to the persistence in the systemic circulation by flow cytometry approaches. 
Another emerging drug class is oligonucleotides.17,18 These are synthetic therapeutics 
comprised of a single strand of deoxyribonucleic acid or ribonucleic acid. Oligonucleotide 
therapies can explicitly target genetic aberrations. Although in oncology, there are no clinically 
approved drugs available, other areas like in the case of patients with rare diseases and 
neurological disorders have shown encouraging results.17 Single-photon emission computed 
tomography imaging of a radiolabeled antisense oligonucleotide (ASO) was studied after 
lumbar intrathecal administration in rats.19 The radiolabeled ASO distributed to the cranium, 
associated with the meningeal lymphatics, egressed through peripheral lymph nodes, and was 
eliminated from the systemic circulation by the kidneys. Molecular imaging in future small-
scale clinical trials using PET imaging may help in better understanding the pharmacological 
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behavior of these novel therapeutics and support their development. However, for all 
indications, the radiation burden has to be taken into account, especially in the non-oncology 
setting. Nevertheless, the development of the total-body PET scanner has led to improved 
sensitivity and allows lower radiation exposure with a similar resolution.20,21 Alternatively, 
non-radioactive labeling with near-infrared fluorophores allows assessing tissue distribution 
in the intraoperative setting.22,23 
Molecular imaging of immune cells to support cancer drug development
Directly radiolabeling a drug of interest to study its biodistribution helps to understand 
its pharmacological behavior. Nevertheless, visualizing pharmacodynamic changes in cell 
populations upon treatment might provide additional information for drug development. The 
field of immunotherapy is rapidly expanding, and many cells of the tumor microenvironment 
are involved. Therefore, several cell populations might be a candidate for pharmacodynamics 
assessment by molecular imaging. Many immunotherapeutics, including T cell-directed 
bispecific antibody-based therapeutics, rely on the cytotoxic potential CD8 T cells to kill 
tumor cells. Imaging CD8 T cells could potentially identify patients likely to respond to 
immunotherapy. Moreover, it might allow to monitor changes in CD8 T cells in the tumor upon 
immunotherapy treatment and thereby identify early responders.24 Multiple clinical trials are 
studying CD8 populations using molecular imaging (e.g., NCT03802123, NCT04029181), 
and first-in-human data (n = 6) has recently been described.25 
Besides cytotoxic T cells, TAMs play an important role in cancer, particularly in breast 
cancer, as summarized in chapter 7. Strategies include the depletion of TAMs but also 
reprogramming macrophages to a more anti-tumoral phenotype. An example of a TAM 
depleting strategy is by targeting CSF1R, a crucial receptor for macrophage survival. In chapter 
8, we describe the distribution of a CSF1R mAb by PET imaging and ex vivo biodistribution. 
CSF1R mAb distributed mainly to the liver and spleen, showing limited tumor selectivity. 
However with a high tracer dose, tumoral macrophages were depleted. Instead of macrophage 
depletion, the anti-tumoral role of macrophages has gained interest. Activation of the signal 
regulatory protein α (SIRPα)-CD47 axis, of which SIRPα is expressed by macrophages and 
CD47 by tumor cells, inhibits phagocytosis by macrophages.26 Another interesting approach 
is the use of macrophages as a cellular therapy. Recently, macrophages with a CAR were found 
to enhance tumor-antigen specific phagocytosis.27 Administration of CAR-macrophages 
resulted in decreased tumor burden and prolonged overall survival in mice bearing a solid 
tumor xenograft.27 
Preclinical models usually do not provide a full context to study the biodistribution 
of immunotherapeutics or specific immune cells with molecular imaging.28 Although 
immunocompetent mouse models can serve to study the interaction between murine tumors 
and the murine immune system, mice are still inherently different from humans. Therefore, 
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